AAM Calls Out Threat Of Consolidation Among Purchasers

Letter To Authorities Accuses Buying Groups And PBMs Of Anticompetitive Activities

Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.

Monopsony text over $100 bills
AAM has accused drug buying groups of creating a monopsony on generics • Source: Alamy

The Association for Accessible Medicines has implored the US Federal Trade Commission and the antitrust division of the Department of Justice to address anticompetitive challenges in the generics industry, in a response to the agencies’ 18 January request for information on how they can modernize enforcement of antitrust laws regarding mergers. (Also see "Merger Enforcement: FTC And Justice Department Casting Wide Net In Considering Changes" - Pink Sheet, 19 January, 2022.)

These problems have been caused by monopsony power of drug buying groups purchasing generic drugs, as well as consolidation, integration...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.